Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients

References

• AbshireTKenetGRecombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitorsJ Thromb Haemost2004289990915140125
   PubMed Web of Science ®Google Scholar
• AledortLMComparative thrombotic event incidence after infusion of recombinant factorVIIa versus factor VIII inhibitor bypass activityJ Thromb Haemost200421700815456478
   PubMed Web of Science ®Google Scholar
• AllenGAledortLTherapeutic decision-making in inhibitor patientsAm J Hematol20068171216369965
   PubMed Web of Science ®Google Scholar
• ArkinSCooperHAHutterJJActivated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use programHaemostasis19982893810087434
   PubMedGoogle Scholar
• ArkinSBleiFFettenJHuman coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitorsBlood Coagul Fibrinolysis200011255910870806
   PubMed Web of Science ®Google Scholar
• AstermarkJEkmanMBerntorpEAntibodies to factor VIIa in patients with haemophilia and high-responding inhibitorsBr J Haematol2002119342712406066
   PubMed Web of Science ®Google Scholar
• BechRMRecombinant factor VIIa in joint and muscle bleeding episodesHaemostasis199626Suppl 113588904188
   PubMedGoogle Scholar
• BerntorpEDonfieldSWatersJThe FEIBA(R) NovoSeven(R) Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by InhibitorsASH Annual Meeting Abstracts2005106324
   Google Scholar
• BlombackBCarlssonKFatahKFibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activationThromb Res199475521387992253
   PubMed Web of Science ®Google Scholar
• CooperHAJonesCPCampionERationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic proceduresHaemophilia200175172211554944
   PubMed Web of Science ®Google Scholar
• EhrenforthSKreuzWScharrerIIncidence of development of factor VIII and factor IX inhibitors in haemophiliacsLancet199233959481347102
   PubMed Web of Science ®Google Scholar
• EhrlichHJHenzlMJGompertsEDSafety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse eventsHaemophilia20028839011952842
   PubMed Web of Science ®Google Scholar
• HednerUFactor VIIa in the treatment of haemophiliaBlood Coagul Fibrinolysis19901307172103315
   PubMedGoogle Scholar
• HednerUDosing and monitoring NovoSeven treatmentHaemostasis199626Suppl 110288904183
   PubMedGoogle Scholar
• HednerUMechanism of action of recombinant activated factor VII: an updateSemin Hematol200643Suppl 1S105716427375
   PubMed Web of Science ®Google Scholar
• HednerUGlazerSPingelKSuccessful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomyLancet1988211932903400
   PubMed Web of Science ®Google Scholar
• HednerUKisielWUse of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitorsJ Clin Invest1983711836416408124
   PubMed Web of Science ®Google Scholar
• HilgartnerMAledortLAndesAEfficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion199030626302402777
   PubMed Web of Science ®Google Scholar
• HvidIRodriguez-MerchanECOrthopaedic surgery in haemophilic patients with inhibitors: an overviewHaemophilia200282889112010425
   PubMed Web of Science ®Google Scholar
• IngerslevJFreidmanDGastineauDMajor surgery in haemophilic patients with inhibitors using recombinant factor VIIaHaemostasis199626Suppl 1118238904185
   PubMedGoogle Scholar
• IngerslevJThykjaerHKudsk JensenOHome treatment with recombinant activated factor VII: results from one centreBlood Coagul Fibrinolysis19989Suppl 1S107109819039
   PubMedGoogle Scholar
• KavakliKMakrisMZulfikarBNovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trialThromb Haemost200695600516601828
   PubMed Web of Science ®Google Scholar
• KenetGLubetskyAGitelSTreatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VIIBlood Coagul Fibrinolysis200011Suppl 1S35810850562
   PubMed Web of Science ®Google Scholar
• KenetGLubetskyALuboshitzJA new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven)J Thromb Haemost20031450512871449
   PubMed Web of Science ®Google Scholar
• KeyNSAledortLMBeardsleyDHome treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitorsThromb Haemost19988091289869160
   PubMed Web of Science ®Google Scholar
• KohlerMThrombogenicity of prothrombin complex concentratesThromb Res1999954 Suppl 1S13710499904
   PubMed Web of Science ®Google Scholar
• KreuzWEttingshausenCEZyschkaAInhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant productsSemin Thromb Hemost2002282859012098090
   PubMed Web of Science ®Google Scholar
• LaurianYGoudemandJNegrierCUse of recombinant activated factor VII as first line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitorsBlood Coagul Fibrinolysis19989155156
   Google Scholar
• LeviMPetersMBullerHREfficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic reviewCrit Care Med2005338839015818119
   PubMed Web of Science ®Google Scholar
• LindleyCMSawyerWTMacikBGPharmacokinetics and pharmacodynamics of recombinant factor VIIaClin Pharmacol Ther199455638488004880
   PubMed Web of Science ®Google Scholar
• LudlamCAThe evidence behind inhibitor treatment with recombinant factor VIIaPathophysiol Haemost Thromb200232Suppl 113812214140
   PubMedGoogle Scholar
• LudlamCASmithMPMorfiniMA prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluationBr J Haematol20031208081312614214
   PubMed Web of Science ®Google Scholar
• LusherJMEarly treatment with recombinant factor VIIa results in greater efficacy with less productEur J Haematol Suppl1998637109882925
   PubMedGoogle Scholar
• LusherJMAcute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VIIBlood Coagul Fibrinolysis200011Suppl 1S45910850564
   PubMed Web of Science ®Google Scholar
• LusherJMFirst and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor developmentSemin Thromb Hemost200228273612098088
   PubMed Web of Science ®Google Scholar
• LusherJMRobertsHRDavignonGA randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study GroupHaemophilia19984790810028299
   PubMed Web of Science ®Google Scholar
• Mauser-BunschotenEPde Goede-BolderAWielengaJJContinuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and BelgiumNeth J Med199853249559883002
   PubMed Web of Science ®Google Scholar
• Mauser-BunschotenEPKoopmanMMGoede-BolderADRecombinant Factor VIIa Data Collection Group. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitorsHaemophilia200286495612199674
   PubMed Web of Science ®Google Scholar
• MayerSABrunNCBegtrupKRecombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhageN Engl J Med20053527778515728810
   PubMed Web of Science ®Google Scholar
• MontoroJBAltisentCPicoMRecombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitorHaemophilia1998476259873885
   PubMed Web of Science ®Google Scholar
• MunroFLJonesHWThe detrimental effect of frequent transfusions in the treatment of a patient with hemophiliaAm J M Sc1943206107
   Google Scholar
• NegrierCGoudemandJSultanYMulticenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing ActivityThromb Haemost199777111399241742
   PubMed Web of Science ®Google Scholar
• NgHJLohSMTanDCThrombosis associated with the use of recombinant activated factor VII:profiling two eventsThromb Haemost2004921448915624250
   PubMed Web of Science ®Google Scholar
• NicolaisenEMAntigenicity of activated recombinant factor VII followed through nine years of clinical experienceBlood Coagul Fibrinolysis19989Suppl 1S119239819042
   PubMedGoogle Scholar
• O’ConnellKAWoodJJWiseRPThromboembolic adverse events after use of recombinant human coagulation factor VIIaJAMA2006295293816418464
   PubMed Web of Science ®Google Scholar
• ParameswaranRShapiroADGillJCHTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society RegistryHaemophilia200511100615810910
   PubMed Web of Science ®Google Scholar
• RiceKMSavidgeGFNovoSeven (recombinant factor VIIa) in central nervous systems bleedsHaemostasis199626Suppl 113148904187
   PubMedGoogle Scholar
• Rodriguez-MerchanECRocinoAEwensteinBConsensus perspectives on surgery in haemophilia patients with inhibitors: summary statementHaemophilia200410Suppl 250215385047
   PubMed Web of Science ®Google Scholar
• SantagostinoEGringeriAMannucciPMHome treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early interventionBr J Haematol199910422610027707
   PubMed Web of Science ®Google Scholar
• SantagostinoEMancusoMERocinoAA prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitorsJ Thromb Haemost200643677116420567
   PubMed Web of Science ®Google Scholar
• ScharrerIRecombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiencyHaemophilia19995253910469179
   PubMed Web of Science ®Google Scholar
• ScharrerIBrayGLNeutzlingOIncidence of inhibitors in haemophilia A patients a review of recent studies of recombinant and plasma-derived factor VIII concentratesHaemophilia199951455410444280
   PubMed Web of Science ®Google Scholar
• SchulmanSBech JensenMFeasibility of using recombinant factor VIIa in continuous infusionThromb Haemost19967543268701403
   PubMed Web of Science ®Google Scholar
• ShapiroADGilchristGSHootsWKProspective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgeryThromb Haemost19988077389843170
   PubMed Web of Science ®Google Scholar
• SjamsoedinLJHeijnenLMauser-BunschotenEPThe effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trialN Engl J Med1981305717216790990
   PubMed Web of Science ®Google Scholar
• SmithMPLudlamCACollinsPWElective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleedingThromb Haemost2001869495311686351
   PubMed Web of Science ®Google Scholar
• VillarAAronisSMorfiniMPharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia AHaemophilia200410352915230949
   PubMed Web of Science ®Google Scholar
• von DepkaMManaging acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safetyHaemophilia200511Suppl 1182316219045
   PubMedGoogle Scholar
• WarrierILusherJMDevelopment of anaphylactic shock in haemophilia B patients with inhibitorsBlood Coagul Fibrinolysis19989Suppl 1S12589819043
   PubMedGoogle Scholar